Member Info for Shukan

https://www.youtube.com/watch?v=8WbgQOEJqwI Exciting times ahead posted tonight by Hemogenyx

“Joint Broker”

Northland Capital Partners Limited as Joint Broker - will be relinquishing its status as Nominated Adviser from 7.am February 1st 2019

added a few more

distressed seller market mechanics I have the hoover out sucked up three lots so far down here

Another 348264 just now added 0.315

Planning granted

Tomorrow it is for Committee: convert two existing villas into C2 supported living including sixteen residential units with office and staff facilities, also single storey rear extension with construction of rear dormers

Certainly difficult to buy even modest chunks most of today -

http://orme-associates.co.uk/wp-content/uploads/2017/12/25-27-South-Drive-Pre-App-Existing-Plans-1.pdf

https://www.thepharmaletter.com/article/orgenesis-optimistic-that-hemogenyx-deal-will-transform-bone-marrow-transplantation

#HEMO looking good here two #Nasdaq quoted Pharma investing in to this little hidden gem 3.5p placing price a year ago spiked to 6p+ in February- what’s over the horizon and funded

ORGS: currently $6.18 a high of $16.80 and a low of $5.06 Royalties of 12% of net revenues generated from Immugenyx tech

indeed ,banned then tried again with a new ID, however you can remember the insults that he through my way one a fool always a fool, Nasdaq boys think differently I did bang the drum here long way to go however invest and wait

NASDAQ: ORGS

According to the terms of the agreement, Orgenesis and/or one or more qualified investors (the "Investors") will advance to Immugenyx a convertible loan in an amount of not less than US$1,000,000 (the "Convertible Loan"). As part of the Agreement, the Investors shall have the right to convert the outstanding Convertible Loan amount into either: (i) shares of Immugenyx at a price per share based on a pre-money valuation of US$8,000,000; or (ii) shares of Orgenesis' common stock at a price per share equal to the weighted average trading price of Orgenesis' common stock for the three trading days preceding conversion. Orgenesis and/or the Investors shall have the option, exercisable at any time up to the third anniversary of the closing of the transaction, to invest additional funds in an amount of up to US$1,000,000 and not less than US$500,000 in Immugenyx.

ahead for shareholders bodes well with respected global Pharma collaborations - note the plural

In 7p February 2018 - do keep DonFranco or is looking at the chart difficult for u

A great buy for a multi-bagger at this level IMO

7Pence February - from low of 2.4p - New Broker on board with a focus on Pharma - according to Vlad company is progressing far better than expected unfortunately as share holders we see it differently with SP down here , but contractually they can not say a dicky bird.